Genmabs SWOT analysis antibody specialists stock faces post-Darzalex challenge - MSN
| GMAB Stock | USD 19.35 0.12 0.62% |
About 62% of Genmab AS's investor base is looking to short. The analysis of overall sentiment of trading Genmab AS stock suggests that many investors are alarmed at this time. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
Genmab |
Genmabs SWOT analysis antibody specialists stock faces post-Darzalex challenge MSN
Read at news.google.com
 |
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Genmab AS is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
| TERN | Terns Pharmaceuticals | 3.10 | ||||
| TVTX | Travere Therapeutics | 3.06 | ||||
| DAWN | Day One | 2.37 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.63 | ||||
| PCVX | Vaxcyte | 0.36 | ||||
| APLS | Apellis Pharmaceuticals | 0.56 | ||||
| BPMC | Blueprint Medicines | 0.68 | ||||
| ALEC | Alector | 2.72 | ||||
| ASND | Ascendis Pharma | 3.39 | ||||
| LEGN | Legend Biotech | 4.40 | ||||
| EWTX | Edgewise Therapeutics | 4.46 | ||||
| AKRO | Akero Therapeutics | 4.53 | ||||
| CYTK | Cytokinetics | 8.41 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |